| 20461-0 |
Pyrazinamide |
Susc |
Isolate |
Pt |
OrdQn |
Method for Slow-growing mycobacteria |
|
ACTIVE |
Pyrazinamide [Susceptibility] by Method for Slow-growing mycobacteria |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
20461-0 |
|
Method for Slow-growing mycobacteria |
|
|
Observation |
|
|
|
0 |
PZA Islt SlowMyco |
|
|
|
|
|
AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; PZA; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 20462-8 |
Streptomycin |
Susc |
Isolate |
Pt |
OrdQn |
Method for Slow-growing mycobacteria |
|
ACTIVE |
Streptomycin [Susceptibility] by Method for Slow-growing mycobacteria |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
20462-8 |
|
Method for Slow-growing mycobacteria |
|
|
Observation |
|
|
|
0 |
Streptomycin Islt SlowMyco |
|
|
|
|
|
AFB; Aminoglycosides; ANTIBIOTIC SUSCEPTIBILITIES; AST; c232; C295; Cidam est; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Novostrep; Point in time; Random; SlowMyco; Solustrep; Streptocol; Strepto-fatol; Streptomyc; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 20463-6 |
Mycobacterium avium complex rRNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Mycobacterium avium complex rRNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20463-6 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
M avium Cmplx rRNA Spec Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Acid Fast; Acid Fast Bacilli; Acid fast bacillus; AFB; Amplif; Amplification; Amplified; Compx; DNA NUCLEIC ACID PROBE; DNA probe; Gen-Probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; M avium; M avium Cmplx; Microbiology; Misc; Miscellaneous; Myco; Mycobact; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; ribosomal RNA; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Tuberculosis; Unspecified |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20464-4 |
Toxoplasma gondii Ab |
Imp |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Toxoplasma gondii Ab [Interpretation] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20464-4 |
|
|
|
|
Observation |
|
|
|
0 |
T gondii Ab Ser-Imp |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; ID; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; Microbiology; Nominal; Point in time; Random; Serum; SR; T gondii; Toxo; Toxoplasmosis |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 20465-1 |
Choriogonadotropin |
MoM |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Choriogonadotropin [Multiple of the median] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
M.o.M |
|
|
|
|
|
|
CHEM |
|
20465-1 |
|
|
|
|
Observation |
|
|
|
0 |
HCG MoM SerPl |
|
|
|
Y |
|
CG; Chemistry; Choriogonadotropins total; Chorionic gonadotropin; HCG; Human chorionic gonadotropin; MoM; Multiple of the median; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
{M.o.M} |
|
|
|
0 |
| 20466-9 |
Estriol.unconjugated |
MoM |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Estriol (E3).unconjugated [Multiple of the median] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
M.o.M |
|
|
|
|
|
|
CHEM |
|
20466-9 |
|
|
|
|
Observation |
|
|
|
0 |
u Estriol MoM SerPl |
|
|
|
Y |
|
Chemistry; E3; Estriol free; Gyn; Gynecology; MoM; Multiple of the median; OB; ObGyn; Obstetrics; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; u Estriol; uE3; Uncnj; Unconj; Unconjug; Unconjugat |
2.73 |
1.0m |
|
|
|
|
|
|
|
{M.o.M} |
|
|
|
0 |
| 20467-7 |
Blood bank alert |
Imp |
^Patient |
Pt |
Nom |
|
|
ACTIVE |
Blood bank alert |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
20467-7 |
|
|
|
|
Observation |
|
|
|
0 |
Blood Bank Alert Patient-Imp |
|
|
|
|
|
Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Point in time; Random |
2.08 |
1.0m |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 20468-5 |
Thiamine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thiamine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L;nmol/L |
|
|
|
|
|
|
CHEM |
|
20468-5 |
|
|
|
|
Both |
|
|
|
0 |
Vit B1 SerPl-sCnc |
|
|
|
Y |
|
c106; c238; Chemistry; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; UniversalLabOrders; Vit B1; Vit B-1; Vitamin B1; Vitamin B-1 |
2.73 |
1.0m |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
| 20469-3 |
Acetone |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Acetone [Presence] in Serum or Plasma by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
20469-3 |
|
Screen |
|
|
Both |
|
|
|
0 |
Acetone SerPl Ql Scn |
|
|
|
|
|
2-propanone; DRUG/TOXICOLOGY; Drugs; Ketone bodies; Me2CO; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; UniversalLabOrders |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 2047-9 |
Carnitine |
MCnc |
Urine |
Pt |
Qn |
|
|
DISCOURAGED |
Carnitine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
2047-9 |
|
|
|
|
Both |
|
|
|
0 |
Carnitine Ur-mCnc |
|
|
|
Y |
|
Carnitine.total; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 20470-1 |
Ethanol |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Ethanol [Presence] in Serum or Plasma by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
20470-1 |
|
Screen |
|
|
Both |
|
|
|
0 |
Ethanol SerPl Ql Scn |
|
|
|
|
|
Alc; Alcohol; DRUG/TOXICOLOGY; Drugs; Ethyl alcohol; EtOH; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20471-9 |
Isopropanol |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Isopropanol [Presence] in Serum or Plasma by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
20471-9 |
|
Screen |
|
|
Both |
|
|
|
0 |
Isopropanol SerPl Ql Scn |
|
|
|
|
|
2-propanol; c615; DRUG/TOXICOLOGY; Drugs; Isopropyl alcohol; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.56 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20472-7 |
Eosinophils |
PrThr |
XXX |
Pt |
Ord |
Wright stain |
|
ACTIVE |
Eosinophils [Presence] in Specimen by Wright stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
20472-7 |
|
Wright stain |
|
|
Observation |
|
|
|
0 |
Eosinophil Spec Ql Wright Stn |
|
|
|
|
|
Eos; Eosin; Eosino; Eosinophil; Eosins; HEMATOLOGY/CELL COUNTS; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; St; Stains; Stn; To be specified in another part of the message; Unspecified; Wright Stn; Wrights |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20473-5 |
Granulocytes |
PrThr |
XXX |
Pt |
Ord |
Wright stain |
|
ACTIVE |
Granulocytes [Presence] in Specimen by Wright stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
20473-5 |
|
Wright stain |
|
|
Observation |
|
|
|
0 |
Granulocytes Spec Ql Wright Stn |
|
|
|
|
|
Gran; Grans; Granulocyte; Granulocytes; HEMATOLOGY/CELL COUNTS; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; St; Stains; Stn; To be specified in another part of the message; Unspecified; Wright Stn; Wrights |
2.79 |
1.0m |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: polymorphonuclear cells is an old term, and not in use anymore. Therefore the decision is to remove polymorphonyclear cells, and replace with Granulocytes; Previous Releases: The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20474-3 |
Bacteria |
Prid |
Tiss |
Pt |
Nom |
Biopsy culture |
|
ACTIVE |
Bacteria identified in Tissue by Biopsy culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20474-3 |
|
Biopsy culture |
|
|
Both |
|
|
|
0 |
Bacteria Tiss Bx Cult |
|
|
|
|
|
Bact; Bx; Bx Cult; C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Point in time; Random; Tissue; Tissue, unspecified; UniversalLabOrders |
2.78 |
1.0m |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
84 |
| 20475-0 |
Cytomegalovirus Ab.IgG |
Imp |
Ser/Plas |
Pt |
Nom |
|
|
ACTIVE |
Cytomegalovirus IgG Ab [Interpretation] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20475-0 |
|
|
|
|
Observation |
|
|
|
0 |
CMV IgG SerPl-Imp |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; CMV; Cytomegalo virus; Cytomgal; HHV-5; Human Herpesvirus-5; ID; Immune globulin G; Immunoglobulin G; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; Microbiology; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
Updated System from Ser to Ser/Plas since this test can also be performed on plasma. |
0 |
| 20476-8 |
Cells.CD1a/Cells |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD1a cells/cells in Blood |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
20476-8 |
|
|
|
|
Observation |
|
|
|
0 |
CD1a Cells NFr Bld |
|
|
|
Y |
|
Blood; CD1a Cells; Cell; CELL MARKERS; Cellularity; HTA1; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; R4; Random; WB; Whole blood |
2.79 |
1.0m |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 20477-6 |
Cells.CD33+CD44+/Cells |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD33+CD44+ cells/cells in Blood |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
20477-6 |
|
|
|
|
Observation |
|
|
|
0 |
CD33+CD44+ Cells NFr Bld |
|
|
|
Y |
|
Blood; CD33 Cells; CD33+CD44+ Cells; Cell; CELL MARKERS; Cellularity; ECMR III; gp67; gp85; H-CAM; Hermes; HUTCH-1; IN-related; LeuM9; Leu-M9; Lu; My9; My-9; Number fraction; p67; Percent; Pgp-1; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.79 |
1.0m |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 20478-4 |
Cells.CD61/Cells |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD61 cells/cells in Blood |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
20478-4 |
|
|
|
|
Observation |
|
|
|
0 |
CD61 Cells NFr Bld |
|
|
|
Y |
|
Beta 3; Beta 3 integrin chain; Beta3; Beta-3 integrin; Blood; CD61 Cells; CD61A; Cell; CELL MARKERS; Cellularity; GPIIb/IIIa; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.79 |
1.0m |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 20479-2 |
Measles virus Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Measles virus IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20479-2 |
|
|
|
|
Both |
|
|
|
0 |
MeV IgG Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; MeV; Microbiology; Msls; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Rubeola; Screen; Serum; SR; UniversalLabOrders |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 2048-7 |
Carnitine/Creatinine |
MRto |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Carnitine/Creatinine [Mass Ratio] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
2048-7 |
|
|
|
|
Observation |
|
|
|
0 |
Carnitine/Creat SerPl |
|
|
|
Y |
|
Carnitine.total; Chemistry; CR; Crea; Creat; Mass concentration ratio; Mass ratio; MCRto; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.42 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 20480-0 |
Benzoylecgonine |
ACnc |
Meconium |
Pt |
Ord |
Screen |
|
DEPRECATED |
Deprecated Benzoylecgonine [Presence] in Meconium by Screen method |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
20480-0 |
|
Screen |
|
|
|
|
|
|
0 |
Deprecated BZE Mec Ql Scn |
|
|
|
|
|
Arbitrary concentration; BEC; BEG; Benz; Benzoylec; BZE; Cocaine degradation production; Cocaine metabolite; Crack metabolite; DRUG/TOXICOLOGY; Drugs; Mec; Ordinal; Point in time; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn |
2.36 |
1.0m |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 20481-8 |
Opiates |
ACnc |
Meconium |
Pt |
Ord |
Screen |
|
DEPRECATED |
Deprecated Opiates [Presence] in Meconium by Screen method |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
20481-8 |
|
Screen |
|
|
|
|
|
|
0 |
Deprecated Opiates Mec Ql Scn |
|
|
|
|
|
Addiction; Arbitrary Concentration; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Heroin; Illicit; Mec; OP; Opi; Opiate; Ordinal; Point in time; PotentialForAbuse; Ql; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn |
2.36 |
1.0m |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 20482-6 |
Granulocytes |
NCnc |
Bld |
Pt |
Qn |
Automated count |
|
ACTIVE |
Granulocytes [#/volume] in Blood by Automated count |
|
MIN |
DefinitionDescription |
|
|
10*9/L |
|
|
|
|
|
|
HEM/BC |
|
20482-6 |
|
Automated count |
|
|
Observation |
|
|
|
0 |
Granulocytes # Bld Auto |
|
|
|
Y |
|
#; ABS; absolute; absolutes; Auto; Automated detection; Blood; Cnt; Count; Count/volume; CT; Elec; Elect; Electr; Gran; Grans; Granulocyte; Granulocytes; HEMATOLOGY/CELL COUNTS; Number concentration; Number Concentration (count/vol); Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
1.0m |
|
|
|
|
|
|
|
10*3/uL |
|
|
|
0 |
| 20483-4 |
Mitochondria Ab |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Mitochondria Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
20483-4 |
|
|
|
|
Both |
|
|
|
0 |
Mitochondria Ab Titr Ser |
|
|
|
Y |
|
ABS; Aby; AMA; Antby; Anti; Antibodies; Antibodies to Microtubule Associated Protein 2; Antibody; Antimitochondrial antibodies; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); Hepatology; Liver; M2; MA; Mito; Mitochon; Mitochond; Mitochondrial; Mitochondrial Ab; PBC; Point in time; Primary Biliary Cirrhosis; Random; S; Serology; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0m |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
